StockData
Filana Therapeutics, Inc. logo

Filana Therapeutics, Inc. (FLNA) stock

FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$0.64+0.08 (+14.52%)

Close on Nov 20, 2026Market cap $30.98MP/E –Yield –

Filana Therapeutics cash

Cash and short-term investments held at the end of each period.

Filana Therapeutics's cash was $82.68M at Jun 30, 2026. For fiscal 2025 it was $95.50M, down 25.7% from the year before. Over ten years it grew 11.8% a year on average. The highest annual figure on record is $233.44M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$95.50M-25.7%
FY2024Dec 31, 2024$128.57M+6.1%
FY2023Dec 31, 2023$121.14M-39.7%
FY2022Dec 31, 2022$201.02M-13.9%
FY2021Dec 31, 2021$233.44M+149.6%
FY2020Dec 31, 2020$93.51M+305.1%
FY2019Dec 31, 2019$23.08M+16.5%
FY2018Dec 31, 2018$19.81M+89.0%
FY2017Dec 31, 2017$10.48M-44.0%
FY2016Dec 31, 2016$18.71M-40.2%
FY2015Dec 31, 2015$31.30M-22.9%
FY2014Dec 31, 2014$40.58M-18.6%
FY2013Dec 31, 2013$49.84M-11.4%
FY2012Dec 31, 2012$56.25M-42.4%
FY2011Dec 31, 2011$97.73M+7.1%
FY2010Dec 31, 2010$91.23M+154.9%
FY2009Dec 31, 2009$35.79M-76.6%
FY2008Dec 31, 2008$153.16M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$82.68M-26.4%
Q1 FY2026Mar 31, 2026$86.57M-26.2%
Q4 FY2025Dec 31, 2025$95.50M-25.7%
Q3 FY2025Sep 30, 2025$106.08M-28.8%
Q2 FY2025Jun 30, 2025$112.38M-45.8%
Q1 FY2025Mar 31, 2025$117.33M-5.5%
Q4 FY2024Dec 31, 2024$128.57M+6.1%
Q3 FY2024Sep 30, 2024$148.98M+4.7%
Q2 FY2024Jun 30, 2024$207.29M+23.1%
Q1 FY2024Mar 31, 2024$124.17M-33.8%
Q4 FY2023Dec 31, 2023$121.14M-39.7%
Q3 FY2023Sep 30, 2023$142.35M-18.5%
Q2 FY2023Jun 30, 2023$168.44M-14.6%
Q1 FY2023Mar 31, 2023$187.47M-10.6%
Q4 FY2022Dec 31, 2022$201.02M-13.9%
Q3 FY2022Sep 30, 2022$174.66M-27.7%
Q2 FY2022Jun 30, 2022$197.23M-29.1%
Q1 FY2022Mar 31, 2022$209.69M-25.7%
Q4 FY2021Dec 31, 2021$233.44M+149.6%
Q3 FY2021Sep 30, 2021$241.52M+903.3%
Q2 FY2021Jun 30, 2021$278.25M+1001.8%
Q1 FY2021Mar 31, 2021$282.19M+1002.3%
Q4 FY2020Dec 31, 2020$93.51M+305.1%
Q3 FY2020Sep 30, 2020$24.07M+35.2%
Q2 FY2020Jun 30, 2020$25.25M+36.3%
Q1 FY2020Mar 31, 2020$25.60M+33.9%
Q4 FY2019Dec 31, 2019$23.08M+16.5%
Q3 FY2019Sep 30, 2019$17.80M-12.9%
Q2 FY2019Jun 30, 2019$18.53M+92.9%
Q1 FY2019Mar 31, 2019$19.13M+78.2%
Q4 FY2018Dec 31, 2018$19.81M+89.0%
Q3 FY2018Sep 30, 2018$20.44M+71.6%
Q2 FY2018Jun 30, 2018$9.61M-31.7%
Q1 FY2018Mar 31, 2018$10.73M-37.8%
Q4 FY2017Dec 31, 2017$10.48M-44.0%
Q3 FY2017Sep 30, 2017$11.92M-45.2%
Q2 FY2017Jun 30, 2017$14.07M–
Q1 FY2017Mar 31, 2017$17.26M–
Q4 FY2016Dec 31, 2016$18.71M–
Q3 FY2016Sep 30, 2016$21.76M–

More Filana Therapeutics figures

See a number that looks wrong?